---
{"dg-publish":true,"permalink":"/0-inbox/cardiovascular-disorder-summary/","created":"2024-02-13T19:46:33.652+07:00","updated":"2025-10-06T19:38:42.982+07:00"}
---


**Author:** ‡∏û‡∏≠‡∏à‡∏≠ c91 rx80 üíò
**Publish Date:**
**Note:** ‡πÇ‡∏õ‡∏£‡∏î‡∏≠‡πà‡∏≤‡∏ô‡∏ï‡∏≤‡∏°‡∏®‡∏£‡∏±‡∏ó‡∏ò‡∏≤ ‡πÅ‡∏•‡∏∞‡∏≠‡∏¢‡πà‡∏≤‡πÇ‡∏õ‡∏£‡∏î‡∏ß‡πà‡∏≤‡∏Å‡∏±‡∏ô‡∏ñ‡πâ‡∏≤‡∏°‡∏µ‡∏™‡∏£‡∏∏‡∏õ‡∏ú‡∏¥‡∏î; summary for PC1 only
‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ó‡∏≥‡∏™‡∏£‡∏∏‡∏õ‡∏Ç‡∏≠‡∏á‡∏´‡∏±‡∏ß‡∏Ç‡πâ‡∏≠ Acute Heart Failure (‡πÅ‡∏ö‡∏ö‡∏¢‡πà‡∏≠), [[2 Areas/University/Heart Failure\|Heart Failure]], [[0 Inbox/Acute coronary syndromes\|Acute coronary syndromes]] ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡∏´‡∏≤‡∏°‡∏±‡∏ô‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏Å‡∏¥‡∏ô ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏™‡∏±‡πâ‡∏ô‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡πÑ‡∏î‡πâ
# Dyslipidemia
- Related Note: [[2 Areas/University/Dyslipidemia\|Dyslipidemia]], [[2 Areas/University/HMG-CoA Reductase Inhibitors (Statins)\|HMG-CoA Reductase Inhibitors (Statins)]], [[2 Areas/University/Fibrates\|Fibrates]]
- Mostly primary dyslipidemia (genetic)
- TC = LDL + VLDL + HDL
	- TG < 400 mg/dl, LDL > 70 mg/dl
	- Patient must be fasting or TG inaccurate!

| Drug | Cholesterol | TG | HDL |
| ---- | ---- | ---- | ---- |
| Thiazide | Increase | Increase |  |
| Progestin | Increase |  |  |
| Estrogen |  | Increase |  |
| Steroid | Increase | Increase | Decrease |
| Isotretinoin |  | Increase | Decrease |

- Pharmacology
	- ASCVD?
		- Age > 75 opinion
		- Age < 75 high statin <70
	- LDL-C >= 190 (Age >= 21)
		- high statin
	- DM, Age 40-75, LDL-C 70-189
		- mod statin
		- ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡∏≠‡∏≤‡∏¢‡∏∏‡∏ä‡πà‡∏ß‡∏á‡∏ô‡∏µ‡πâ‡∏à‡∏∞‡∏û‡∏¥‡∏à‡∏≤‡∏£‡∏ì‡∏≤‡∏£‡∏≤‡∏¢‡∏Ñ‡∏ô
	- ASCVD Risk >= 7.5%, LDL 70-189, no DM or clinical ASCVD
		- 7.5 - 20 Mod
		- 20 High
- ‡∏´‡∏≤‡∏Å LDL ‡πÑ‡∏°‡πà‡πÄ‡∏Ç‡πâ‡∏≤ target ‡∏™‡∏±‡∏Å‡∏ó‡∏µ try add PCSK9 inhibitors or Ezetimbe
- Managing -statin side effects (2016 ESC/EAS)
	- If ALT < 3 ULN, continue statin, keep monitoring
	- If ALT > 3 ULN, stop statin
	- If CK x 4 ULN, do not start statin
	- If myositis and CK x 5 ULN, might be rhabdomyolysis
- Hypertriglyceridemia
	- ‡∏ñ‡πâ‡∏≤‡πÄ‡∏Å‡∏¥‡∏ô 500 ‡πÉ‡∏´‡πâ‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏£‡∏≤‡∏Å‡∏•‡∏±‡∏ß pancreatitis
	- ‡πÅ‡∏ï‡πà ESC 2021 said: >200 ‡πÉ‡∏´‡πâ‡πÄ‡∏£‡∏¥‡πà‡∏° lifestyle mod, ‡∏ñ‡πâ‡∏≤‡∏¢‡∏±‡∏á‡∏•‡∏î‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ n-3 PUFAs ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà icosapent ethyl 2 g/d ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏´‡πâ add fenofibrate
	- ‡πÉ‡∏´‡πâ fenofibrate / bezafibrate
	- ‡∏´‡∏≤‡∏Å‡∏Å‡∏¥‡∏ô fibrate ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏Å‡∏¥‡∏ô fish oil > 2g/d ‡πÅ‡∏ó‡∏ô‡πÑ‡∏î‡πâ
- Pharmacology
	- statin
		- ‡∏•‡∏î 1/2 if eGFR < 45
		- Atorvastatin / Rosuvastatin ‡∏ó‡∏≤‡∏ô‡∏ï‡∏≠‡∏ô‡πÄ‡∏ä‡πâ‡∏≤‡πÑ‡∏î‡πâ
		- Pravastatin safest from DI
		- Rosuvastatin weak CYP2C9
		- Atorvastatin, Simvastatin, Lovastatin CYP3A4
	- Ezetimibe
		- cholesterol absorption inhibitor (via transport protein NPC1L1)
	- PCSK9-inhibitors
		- ‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á PCSK9 ‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ LDL receptor ‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏•‡∏≤‡∏¢
	- Gemfibrozil
		- **‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö -statin ‡∏ó‡∏±‡πâ‡∏á‡∏Å‡∏•‡∏∏‡πà‡∏°**
		- unknown mech
		- fenofibrate doesn‚Äôt show the same risk
	- eGFR < 45
		- Statin ‡∏•‡∏î‡πÇ‡∏î‡∏™‡∏Ñ‡∏£‡∏∂‡πà‡∏á‡∏´‡∏ô‡∏∂‡πà‡∏á
		- Fenofibrate ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ
		- Gemfibrozil ‡∏•‡∏î‡∏Ñ‡∏£‡∏∂‡πà‡∏á‡∏ô‡∏∂‡∏á

 
# Hypertension
- Related Note: [[2 Areas/University/Hypertension\|Hypertension]]
- Thai Hypertension Staging
	- more than 130/80 -> High Normal
	- more than 140/90 -> Stage 1
	- more than 160/100 -> Stage 2
	- more than 180/110 -> Definite HTN (Hypertension Crisis)
	- ‡∏ñ‡πâ‡∏≤ HBPM -> 135/85 ‡∏à‡∏∞‡∏ñ‡∏∑‡∏≠‡∏ß‡πà‡∏≤ High
- Goal:
	- Age: 65 ‡∏Ç‡∏≠‡∏á‡∏ù‡∏£‡∏±‡πà‡∏á‡∏Ç‡∏¢‡∏±‡∏ö‡πÄ‡∏õ‡πá‡∏ô 70
	- ‡∏ñ‡πâ‡∏≤‡πÄ‡∏Å‡∏¥‡∏ô or CKD ‡πÉ‡∏´‡πâ < 140/90
	- ‡∏ñ‡πâ‡∏≤‡∏ô‡∏≠‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡πÉ‡∏´‡πâ < 130/80
- Diagnosis:
	- High Normal -> HBPM
	- Stage 1 or Stage 2 -> HBPM or OBPM
	- If 2 serial high, then Dx HTN
	- Or assess risk of CVD, and Dx HTN
- Hypertension Emergency
	- more than 180/120 + sign of target organ damage ‡πÉ‡∏´‡πâ admit ICU and reduce BP ASAP
	- aortic dissection -> aggressively reduce ‡πÑ‡∏°‡πà‡∏á‡∏±‡πâ‡∏ô‡∏ï‡∏≤‡∏¢
	- ‡∏ô‡∏≠‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏•‡∏î sBP 25% in 1 hour
- Treatment First-line:
	- ACEi or ARB + CCB
	- ACEi or ARB + Diuretics
- Resistant Hypertension
	- ‡πÉ‡∏ä‡πâ hypertensive medication 3 ‡∏ï‡∏±‡∏ß‡πÅ‡∏•‡πâ‡∏ß**‡πÇ‡∏î‡∏¢‡∏°‡∏µ diuretics ‡πÄ‡∏õ‡πá‡∏ô 1 ‡πÉ‡∏ô‡∏ô‡∏±‡πâ‡∏ô** ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô resistant hypertension -> add spironolactone ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏≠‡∏≤‡∏à‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡∏™‡∏π‡∏á‡∏à‡∏≤‡∏Å‡∏†‡∏≤‡∏ß‡∏∞ hyperaldosteronism

# Thromboembolic Disorders
- Related Note: [[0 Inbox/Thromboembolic Disorders\|Thromboembolic Disorders]], [[0 Inbox/Anticoagulant\|Anticoagulant]]
- Assess Risk of mortality
	- High: Thrombolytics Rescue then UFH or LWMH and anticoagulant
	- Intermediate-Low: Use standard regimen ‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢ ‡∏™‡∏±‡∏Å‡∏≠‡∏±‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢‡∏ï‡∏≤‡∏°‡∏à‡∏±‡∏¢‡∏ä‡∏≠‡∏ö ‡∏≠‡∏¥‡∏≠‡∏¥
- Standard Regimen
	- LMWH or UFH 5d overlap with Warfarin
	- LMWH or UFH 5d then Dabigatran or Edoxaban
	- Rivaroxaban monotherapy
	- Apixaban monotherapy
- [[0 Inbox/Anticoagulant\|Anticoagulant]]
	- VKA can be used in long-term, do not use in acute since slow onset, have to bridge with NOACs
- Duration of Treatment:
	- 3 months, extend if high risk of VTE: active cancer, phospholipid syndrome
# Peripheral Arterial Disease
- Related Note: [[0 Inbox/Peripheral Arterial Disease\|Peripheral Arterial Disease]]
- Use Ankle-brachial index (ABI) : (ankle BP / brachial BP)
- claudication: reduced blood flow to the limb, generally legs
	- pain like cramping
	- pain develop when muscle is moved
	- pain resolve usually within 10 minutes of discontinuation of exercise or resting
- Classification
	- Asymptomatic ABI < 0.9
	- Symptomatic ABI < 0.85 with Sx or Hx of peripheral vascularization
- Treatment ***‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏°‡∏±‡πà‡∏ô‡πÉ‡∏à‡πÉ‡∏î ‡πÜ ‡∏ó‡∏±‡πâ‡∏á‡∏™‡∏¥‡πâ‡∏ô‡∏ß‡πà‡∏≤‡∏ñ‡∏π‡∏Å‡∏°‡∏±‡πâ‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏û‡∏µ‡πÄ‡∏à‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡πÄ‡∏•‡∏¢***
	- Carotid Artery Stenosis
		- Asymptomatic (‡∏ï‡∏µ‡∏ö >= 50% and low risk bleedings): SAPT (ASA OR CLOP)
		- Symptomatic
			- Stent: 1 month DAPT (ASA + CLOP) then SAPT
			- Surgery: Long term SAPT
	- Stable Symptomatic Lower Extremity PAD
		- Asymptomatic ‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤
		- Symptomatic
			- High risk of ischemic event: Rivaroxaban 2.5 mg bid + ASA od
			- High risk of bleeding risk or CI to Rivaroxaban: SAPT (Clopidogrel > ASA)
			- High risk of vascular event: DAPT for at least 1 month
			- Revascularization: VKA or SAPT
			- No risk of ischemic event: Rivaroxaban 2.5 mg bid + ASA od OR¬†**SAPT**
# Atrial Fibrillation
- Related Note: [[0 Inbox/Atrial fibrillation\|Atrial fibrillation]], [[0 Inbox/Anticoagulant\|Anticoagulant]], [[2 Areas/University/Beta-blockers\|Beta-blockers]], [[0 Inbox/Antiarrhythmic\|Antiarrhythmic]]
- Etiology: abnormal electric activity at atrium 
- **Rhythm can be both regular and irregular**
- ABC = Avoid Stroke, Better Symptoms control, (Manage) Comorbidities
- Diagnosis: ‡πÉ‡∏´‡πâ‡∏´‡∏°‡∏≠‡∏ó‡∏≥‡πÄ‡∏´‡∏≠‡∏∞ ‡πÅ‡∏ï‡πà‡πÄ‡∏≠‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏ß‡πà‡∏≤‡∏°‡∏±‡∏ô‡∏à‡∏∞‡∏°‡∏µ Atrial Flutter ‡∏î‡πâ‡∏ß‡∏¢‡∏ô‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏•‡∏±‡∏Å‡∏©‡∏ì‡∏∞ EKG ‡πÅ‡∏ö‡∏ö saw tooth ‡πÅ‡∏ï‡πà‡πÅ‡∏¢‡∏Å‡πÉ‡∏´‡πâ‡∏≠‡∏≠‡∏Å‡∏Å‡πá‡∏û‡∏≠‡∏ß‡πà‡∏≤ rhythm regular ‡∏°‡∏±‡πâ‡∏¢ ‡∏ñ‡πâ‡∏≤‡∏°‡∏±‡∏ô irregular ‡∏Ñ‡∏ß‡∏£‡πÉ‡∏™‡πà rhythm control ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏°‡∏±‡∏ô‡∏õ‡∏Å‡∏ï‡∏¥‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏Ñ‡πà‡πÑ‡∏°‡πà normal sinus ‡πÅ‡∏ï‡πà tachycardia ‡∏Å‡πá‡πÉ‡∏™‡πà rate control
- EHRA Scale:
	- 1 None -> ‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£
	- 2A Mild -> ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£
	- 2B Moderate -> ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÅ‡∏ï‡πà‡∏£‡∏≥‡∏Ñ‡∏≤‡∏ç‡πÄ‡∏â‡∏¢ ‡πÜ
	- 3 Severe -> ‡∏Å‡∏£‡∏∞‡∏ó‡∏ö daily life
	- 4 Disabling
- Treatment:
	- Anti Arrhythmic Class
		- Class 1c: Na channel block (slow)
		- Class 2: beta blockers
		- Class 3: K+ channel blocker
		- Class 4: Ca2+ channel blocker
		- Class 5: other mechanism
	- Rate Control
		- choose agent depend on patient comorbidities (asthma, HF)
		- first line: beta blocker (class 2): propranolol, esmolol, atenolol
		- alternative: non-DHP CCB (class 4), Digoxin (class 5), Amiodarone (class 1,2,3,4)
	- Rhythm Control
		- DCC (Direct Current Cardioversion) if hemodynamically unstable
		- Medication (use Class 1c and Amiodarone)
			- Flecainide, Propafenone (Class 1c) (Preferred in HTN or other cases)
			- Amiodarone (class 1,2,3,4) (Preferred in HF)
- Amiodarone
	- CYP3A4 and p-gp inhibitors
	- can cause phlebitis: remove, warm compress, insert at other arm (‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà stable ‡∏à‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏≤‡∏™‡∏ô‡πÉ‡∏à)
- Stroke Prophylaxis (non-valvular AF)
	- CHA2DS2-VASc
		- Male >= 2, Female >=3
		- Add OAC 
		- If CrCl < 15 use Warfarin or Apixaban
	- HAS-BLED
		- If >= 3, use low dose OAC
- Valvular AF stroke prophylaxis
	- Use VKA
- VKA: [[0 Inbox/Warfarin\|Warfarin]]
	- Enoxaparin: 1.5 mg/kg od or 1 mg/kg bid
- OACS: DARE
	- Direct Thrombin inhibitors
		- **D**abigatran
			- 150 mg bid --if high risk bleeding--> 110 mg bid
	- Factor Xa inhibitors
		- **A**pixaban
			- 5 mg bid --if high risk bleeding--> 2.5 mg bid
			- high risk criteria (2 of 3): age>= 80, wt <= 60, SCr >= 1.5
		- **R**ivaroxaban
			- 20 mg od --if high risk bleeding --> 15 mg od
			- or adjust by renal if eGFR < 50
		- **E**doxaban
			- ‡∏Ç‡∏±‡∏ö‡∏ó‡∏≤‡∏á‡πÑ‡∏ï‡πÄ‡∏¢‡∏≠‡∏∞‡∏°‡∏≤‡∏Å ‡∏ñ‡πâ‡∏≤ CrCl ‡∏™‡∏π‡∏á‡πÑ‡∏õ‡∏Å‡πá‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡πÑ‡∏°‡πà‡∏î‡∏µ
			- 60 mg od--if high risk bleeding--> 30 mg od
			- high risk criteria: wt <= 60
			- or adjust by renal if eGFR < 50
	- NG Tube: **A R E**
	- Liver child-pugh B: **‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ R** (Rivaroxaban ‡∏ä‡∏≠‡∏ö renal ‡πÄ‡∏•‡∏¢‡πÑ‡∏°‡πà‡∏ä‡∏≠‡∏ö‡∏ï‡∏±‡∏ö‡∏û‡∏±‡∏á)
	- Liver child-pugh C: **‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡∏ó‡∏∏‡∏Å‡∏ï‡∏±‡∏ß**
	- Intermittent Hemodialysis: **A**
	- Stage 4 CKD: **‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ D** ‡∏ô‡∏≠‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏≠‡∏≤‡∏à‡∏¢‡∏±‡∏á‡πÑ‡∏î‡πâ‡∏≠‡∏¢‡∏π‡πà ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ Stage 5 or hemodialysis ‡πÑ‡∏õ A ‡πÄ‡∏•‡∏¢‡∏à‡∏£‡πâ‡∏≤
	- p-gp inhibitors: Factor Xa ‡∏ó‡∏∏‡∏Å‡∏ï‡∏±‡∏ß
	- CYP3A4: Warfarin, **A R**
	- Safest for drug interaction: **D** and **E**
	- Require the use of UFH or LWMH 5 days before using these drug in DVT: **D** and **E**

# Ischemic Stroke
- Related Note: [[2 Areas/Pharmacy/Disease/Ischemic Stroke\|Ischemic Stroke]], [[0 Inbox/Anticoagulant\|Anticoagulant]]
- Throat Classification:
	- Cardiogenic Stroke
	- Large artery atherosclerosis Stroke
	- Small-vessel stroke (Lacunar)
	- Cryptogenic stroke (ESUS)
- Recurrent TIA Risk: ABCD2
	- 6-7 high ‡∏°‡∏µ role of DAPT
- NIHSS Score (0-42)
- mRS to assess quality of life (0-6)
- Acute Management:
	- Mechanical Thrombectomy: in 6 hours (MCA, ICA ‡∏™‡πà‡∏ß‡∏ô‡∏ï‡πâ‡∏ô)
	- Fluid Replenishment, stop BP medication to avoid too low BP
	- BP Target:
		- Fibrinolytics planned: 185/110 mmHg
		- During: 180/105 mmHg
		- Mechanical: 180/105 mmHg
		- No fibrinolytics: 220/120 mmHg
	- BP Control meds:
		- Labetalol IV push
		- Nicardipine (max 15mg/h)
	- Fibrinolytics
		- Alteplase ‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏µ indication ‡∏ï‡∏±‡∏ß‡∏≠‡∏∑‡πà‡∏ô‡πÑ‡∏°‡πà‡πÄ‡∏≠‡∏≤!
		- 0.9 mg/kg 10% IV bolus and 90% IV drip in 1 hour
		- Mild disabling stroke? (NIHSS 0-4) ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ alteplase to reverse aphagia, cognitive, blindness, weakness symptoms
		- NIND: within 3 hour
		- ECASS 3: within 4.5 hour
		- ENHANCTED: low dose 0.8 mg/kg 15% IV bolus then 85% IV drip in 1 hour ‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å standard dose
		- WAKE-UP: MRI Mismatch or **4.5 - 24 hours** ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÅ‡∏ö‡∏ö standard dose ‡πÑ‡∏î‡πâ‡∏≠‡∏¢‡∏π‡πà
	- No Fibrinolytics (and not cardiogenic) **& NIHSS <= 3**
		- CHANCE: Start within **24 hours**, ASA + CLOP 300 then ASA+CLOP 75 for 21 days
		- POINT: Start within 12 hours, ASA + CLOP 600 then ASA+CLOP 75 for 90 days
		- THALES: Start within 24 hours, ASA + Tica 180 then ASA + Tica 90 bid for 30 days
- Long-term management:
	- IF Fibrinolytics given: When to mono antiplatelet?
		- Start in 24-48 hours after fibrinolytics
		- confirm hypodense or bleeding first
		- Aspirin or Clopdiogrel
	- IF Fibrinolytics given: When to start DAPT?
		- start ‡∏ï‡∏≤‡∏° CHANCE, POINT, THALES ‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢
		- ‡∏ñ‡πâ‡∏≤ Large Artery Artherosclerosis ‡∏Å‡πá‡πÉ‡∏™‡πà‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà prefer ASA monotherapy ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏à‡∏∞ bleed ‡πÄ‡∏Å‡∏¥‡∏ô‡πÑ‡∏õ
	- IF Atrial Fibriliation:
		- Start anticoagulant
- Other Medications:
	- Cilostazol: PDE-3 inhibitor, do not use in HF, preffered in Lacunar Stroke
	- Ibuprofen: 8 hr before aspirin, 30 min after aspirin
# Shock
- Related Note: [[0 Inbox/Shock (hypovolemic, cardiogenic and septic)\|Shock (hypovolemic, cardiogenic and septic)]]
- Shock Criteria
	- sBP <= 90 mmHg or decrease >= 40% with enough fluid resuscitation or on vasopressor
	- MAP <= 65 mmHg or decrease >= 20% baseline
		- MAP = COxSVR + CVP or 1/3 sBP + 2/3 dBP
- Fluid Evaluation
	- CVP Normal 8-12 mmHg
		- if doc found % IVC Collapse > 50%, or IVC < 2 cm, suggesting CVP at 0-10 mmHg
		- Low value, suggesting **volume depletion**
- Distributive Shock; most commonly; septic shock
	- Sepsis 
		- SIRs (2of4) (4T)
			- Temperature <36 or >38
			- Tachycardia > 90
			- Tachypnea > 20
			- Total Leukocyte count < 4000 or > 12000
		- Documented Infection
	- When to call "Septic Shock?"
		- adequate fluid resuscitation
		- vasopressor required to maintain MAP >= 65 mmHg
		- lactase >= 2 mmol/L
	- 1-hour bundle
		- broad spectrum-antibiotics within 1 hour (**‡∏ñ‡πâ‡∏≤ shock or sepsis ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÉ‡∏î‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏´‡∏ô‡∏∂‡πà‡∏á‡∏Å‡πá‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏´‡πâ**)
		- 30 ml/kg balanced crystalloid for hypotension within 3 hour (1 hour in severe case)
		- apply vasopressor to maintain MAP >= 65 mmHG
			- 1st line: NE ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏ä‡πâ‡∏≤ ‡∏£‡∏µ‡∏ö‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢
			- not responsive?: add vasopressin + hydrocortisone 200 mg/day (‡∏´‡∏£‡∏∑‡∏≠ NE >= 0.25 mcg/kg/min for 4 hours ‡∏Å‡πá‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ‡πÅ‡∏•‡πâ‡∏ß)
			- ‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡πÄ‡∏Ç‡πâ‡∏≤‡∏≠‡∏µ‡∏Å‡∏Å‡πá epinephrine
			- ‡πÑ‡∏°‡πà‡πÄ‡∏Ç‡πâ‡∏≤‡∏≠‡∏µ‡∏Å‡∏Å‡πá phenyephrine
- Hypovolemic Shock
- Cardiogenic Shock
	- High PCWP, but hypovolemia will be low PCWP
	- Criteria:
		- SBP < 90 or require support for >= 90 mmHg
		  AND
		  hypoperfusion (urine output < 30ml/h / Lactate > 2mmol/L / Cold extremities / decreased mental state)
	- **Mostly cold and wet**
	- Commonly use **Dobutamine**, no difference in Milrinone and Dobutamine (both medications are **inodilators**)
- Obstructive Shock